RGNX insider transaction filings
REGENXBIO Inc. — 49 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-04. Screen RGNX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-04 | 4 | PAKOLA STEVE — Chief Medical Officer | Tax withholding (F): 7,468 @ $9.69 | EDGAR |
| 2026-08-04 | 4 | Christmas Patrick J. — Chief Strategy & Legal Officer | Tax withholding (F): 4,699 @ $9.69 | EDGAR |
| 2026-07-06 | 4 | PAKOLA STEVE — Chief Medical Officer | Option exercise (M): 2,161 @ $7.86 · Sale (S): 2,161 @ $13.64 · Option exercise (M): 2,161 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Simpson Curran — Chief Executive Officer, Director | Grant/award (A): 951 @ $7.00 · Grant/award (A): 1,453 @ $10.18 · Tax withholding (F): 6,818 @ $13.09 | EDGAR |
| 2026-07-01 | 4 | PAKOLA STEVE — Chief Medical Officer | Sale (S): 19,608 @ $11.04 · Option exercise (M): 36,725 @ $7.86 · Sale (S): 36,725 @ $12.86 · Option exercise (M): 36,725 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Bennett Jean — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Zachary Jennifer — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Glucksmann Alexandra — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Fox Allan M. — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Mills Kenneth T. — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Tasse Daniel — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | STUMP DAVID C — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | KARABELAS ARGERIS N — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | MIGAUSKY GEORGE V — Director | Grant/award (A): 9,807 @ $0 · Grant/award (A): 46,600 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | PAKOLA STEVE — Chief Medical Officer | Sale (S): 15,309 @ $11.02 | EDGAR |
| 2026-03-12 | 4 | PAKOLA STEVE — Chief Medical Officer | Sale (S): 5,124 @ $10.35 | EDGAR |
| 2026-02-03 | 4 | PAKOLA STEVE — Chief Medical Officer | Tax withholding (F): 5,267 @ $11.16 | EDGAR |
| 2026-02-03 | 4 | Christmas Patrick J. — Chief Strategy & Legal Officer | Tax withholding (F): 4,700 @ $11.16 | EDGAR |
| 2026-01-29 | 4 | Mills Kenneth T. — Director | Option exercise (M): 225,000 @ $13.09 · Tax withholding (F): 221,753 @ $13.41 · Option exercise (M): 225,000 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Malzahn Craig — Chief Technology Officer | Grant/award (A): 65,847 @ $0 · Grant/award (A): 35,402 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Chan Mitchell — Chief Financial Officer | Grant/award (A): 73,749 @ $0 · Grant/award (A): 39,650 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | PAKOLA STEVE — Chief Medical Officer | Grant/award (A): 65,847 @ $0 · Grant/award (A): 35,402 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Christmas Patrick J. — Chief Strategy & Legal Officer | Grant/award (A): 73,749 @ $0 · Grant/award (A): 39,650 (derivative) @ $0 | EDGAR |
| 2026-01-08 | 4 | Simpson Curran — Chief Executive Officer, Director | Grant/award (A): 144,864 @ $0 · Grant/award (A): 233,651 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Malzahn Craig — Chief Technology Officer | Tax withholding (F): 1,238 @ $14.40 | EDGAR |
| 2026-01-06 | 4 | PAKOLA STEVE — Chief Medical Officer | Tax withholding (F): 18,247 @ $14.40 | EDGAR |
| 2026-01-06 | 4 | Christmas Patrick J. — Chief Strategy & Legal Officer | Tax withholding (F): 9,793 @ $14.40 | EDGAR |
| 2026-01-06 | 4 | Simpson Curran — Chief Executive Officer, Director | Tax withholding (F): 18,559 @ $14.40 | EDGAR |
| 2025-10-10 | 4 | Simpson Curran — Chief Executive Officer, Director | Sale (S): 20,811 @ $12.62 | EDGAR |
| 2025-10-01 | 4 | Simpson Curran — Chief Executive Officer, Director | Sale (S): 7,624 @ $10.03 | EDGAR |
| 2025-09-12 | 4 | Simpson Curran — Chief Executive Officer, Director | Sale (S): 7,734 @ $10.02 | EDGAR |
| 2025-09-03 | 4 | Malzahn Craig — Chief Technology Officer | Tax withholding (F): 234 @ $8.93 | EDGAR |
| 2025-09-03 | 4 | Chan Mitchell — Chief Financial Officer | Tax withholding (F): 4,901 @ $8.93 | EDGAR |
| 2025-08-04 | 4 | Christmas Patrick J. — Chief Strategy & Legal Officer | Tax withholding (F): 4,699 @ $8.19 | EDGAR |
| 2025-07-03 | 4 | Simpson Curran — Chief Executive Officer, Director | Tax withholding (F): 4,701 @ $8.23 | EDGAR |
| 2025-06-03 | 4 | Fox Allan M. — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Zachary Jennifer — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Mills Kenneth T. — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Glucksmann Alexandra — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Bennett Jean — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Tasse Daniel — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | STUMP DAVID C — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | KARABELAS ARGERIS N — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | MIGAUSKY GEORGE V — Director | Grant/award (A): 7,768 @ $0 · Grant/award (A): 39,815 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | Mills Kenneth T. — Director | Option exercise (M): 20,602 @ $3.76 · Sale (S): 20,602 @ $7.91 · Option exercise (M): 20,602 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | PAKOLA STEVE — Chief Medical Officer | Tax withholding (F): 5,263 @ $8.07 | EDGAR |
| 2025-04-04 | 4 | Danos Olivier — Chief Scientific Officer | Tax withholding (F): 5,452 @ $8.07 | EDGAR |
| 2025-04-04 | 4 | Christmas Patrick J. — Chief Legal Officer | Tax withholding (F): 4,700 @ $8.07 | EDGAR |
| 2025-03-31 | 4 | Mills Kenneth T. — Director | Option exercise (M): 30,752 @ $3.76 · Option exercise (M): 30,752 (derivative) @ $0 | EDGAR |
Recent 8-K events — REGENXBIO Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RGNX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →